BlackRock Advisors’s Seres Therapeutics MCRB Stock Holding History

BlackRock Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$185K	Sell	935 -25	-3%	-$5.45K	﹤0.01%	2749
2016 Q3	$236K	Sell	960 -1,974	-67%	-$693K	﹤0.01%	2595
2016 Q2	$1.7M	Sell	2,934 -29,578	-91%	-$17.4M	﹤0.01%	1507
2016 Q1	$17.3M	Buy	32,512 +15,468	+91%	+$8.07M	0.02%	588
2015 Q4	$12M	Buy	17,044 +123	+0.7%	+$80.8K	0.01%	736
2015 Q3	$10M	Sell	16,921 -15,482	-48%	-$12.6M	0.01%	784
2015 Q2	$26.9M	Buy	+32,403	New	+$28.3M	0.03%	449

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock Advisors's MCRB Position: Q4 2016 in Review

BlackRock Advisors reduced its Seres Therapeutics (MCRB) stake by 2.6% in Q4 2016, selling an estimated $5.45K and leaving 935 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

BlackRock Advisors first reported a position in MCRB in Q2 2015 and has held it in 7 quarters since. The position peaked at $26.9M in Q2 2015. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

BlackRock Advisors held 935 shares of Seres Therapeutics worth $185K as of Q4 2016.
BlackRock Advisors sold 25 Seres Therapeutics shares in Q4 2016, an estimated $5.45K.
Seres Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2749 holding.
BlackRock Advisors first reported a position in Seres Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's Seres Therapeutics position peaked at $26.9M in Q2 2015.
89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.